Teva Wins Court Ruling Against Opiant, Emergent Bio On Narcan Nasal Spray
UBS raises Teva price target - Globes
Teva Stock Could Reach $100 | Barron's
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets | Business Wire
Teva Reports Fourth Quarter and Full Year 2022 Financial Results | Business Wire
Teva- Pharmaceutical Industries Ltd. - ADR Stock Forecast: down to 7.941 USD? - TEVA Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis
Analyst Ratings for Teva Pharmaceutical Indus | Markets Insider
Teva Pharmaceutical Industries Ltd (ADR) Announces the Launch of Generic Equivalents to Syprine
Teva jumps after Wall Street upgrades, analysts say stock 'too cheap to ignore'
Teva Pharmaceutical: The Babe Ruth of the Investment World (NYSE:TEVA) | Seeking Alpha